Cancer Drug Completes First Arm of Pivotal 28-Day Study, Gives Hope for Cure
(NewsUSA) - A potentially new cure for cancer is one step closer to market, giving hope to the the 14 million people battling the incurable disease.
The Australian-based biotech company, Propanc Health Group (OTCQB: PPCH), which has been developing proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian, and colorectal cancers, recently completed a 28-day toxicokinetic study to support a safe starting dose in patients, as it marches toward clinical trials in 2017 for its lead product, PRP.
Data from the study will form the basis of a clinical trial application in the United Kingdom and define conditions for a planned four-week regulatory Good Laboratory Practice compliant toxicology study, with results expected in early 2017.
Studies of this type are an important part of the development process for new therapeutic agents prior to clinical testing in humans.
"We are making excellent progress completing these studies for PRP," says James Nathanielsz, Propanc's chief executive officer. "Preclinical efficacy is well-established and the safety studies are pivotal because they provide the rationale for a safe starting dose for patient trials."
Propanc's proenzyme product, PRP, has the potential to be a game-changer for cancer care by offering an effective option for long-term therapy without the excessive toxicity associated with many current cancer treatments.
"My scientific colleagues and I believe a cancer stem cell targeting therapy, which reduces chemo-resistance and supports immune function could become a significant addition to the treatment process," says Dr. Julian Kenyon, Propanc's chief scientific officer. "PRP is going to be a part of many different cancer combinatorial regimes, which is why we're keen to follow up on the immuno-biological aspects of PRP in future trials."
For more information on PPCH, visit www.propanc.com.
|Link to this article: Copy and paste the following code
|Embed this article: